8-K current report · filed Jul 30, 2026

CASTLE BIOSCIENCES INC (CSTL) 8-K Current Report: July 30, 2026

Item 2.02Item EX-99.1Item EX-99.2Item 7.01CSTL overview

Short answer

CASTLE BIOSCIENCES INC (CSTL) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Q2 2026 results for quarter ended June 30, 2026 released July 30, 2026.

CASTLE BIOSCIENCES INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 released July 30, 2026
  • Detailed financial results and management commentary contained in Exhibit 99.1
  • Results provided under Regulation FD through a press release, not Section 18 “filed” information

Item 7.01 · Regulation FD Disclosure

  • Exhibit 99.2 presents Castle Biosciences’ investor presentation
  • Management may use the materials in future investor meetings
  • Investor relevance depends on presentation content, including updated strategy, operating performance or outlook

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $103.5M, up from $86.2M, with core test reports up 32%
  • TissueCypher reports surged to 14,988 from 9,170, offsetting modest DecisionDx-Melanoma growth
  • 2026 revenue guidance raised to $365–375M from $345–355M, signaling stronger demand expectations
  • Profitability outlook improved with positive Adjusted EBITDA expected in Q3, Q4 and full-year 2026
  • Q2 GAAP net loss $2.1M versus $4.5M income, while Adjusted EBITDA rose to $12.4M from $10.4M

Item EX-99.2 · Exhibit EX-99.2

  • 2Q26 revenue $103.5M, adjusted EBITDA $12.4M and operating cash flow $15.2M, demonstrating profitability and cash generation
  • 2026 revenue guidance raised to $365-375M from $345-355M, signaling stronger expected demand and execution
  • Core test volumes increased 32% year over year, led by TissueCypher growth to 14,988 reports from 9,170
  • Cash, equivalents and marketable securities totaled $266.8M as of June 30, 2026, supporting internal funding of commercial and pipeline investments
  • AdvanceAD-Tx received NYSDOH assay approval, expanding access to Castle’s atopic dermatitis treatment-selection test

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CASTLE BIOSCIENCES INC 8-K filings

Get the next CSTL 8-K as it lands

Follow CSTL for push alerts, or ask the research agent what this filing means.